Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
Psoriatic arthritis (PsA) is unique inflammatory arthritis that affects up to 20 percent of patients with psoriasis. Although it has the potential to cause severe joint destruction, it is often underdiagnosed and undertreated, particularly because PsA is less responsive to FDA-approved therapies than psoriatic skin disease. Additionally, psoriasis is associated with a number of other extracutaneous features that can increase morbidity and mortality in PsA patients. This session will briefly review the various presentations of PsA in patients with different types of psoriatic skin disease. Faculty presentations will be followed by a discussion of treatment options for patients with PsA, as well as screening requirements for associated comorbidities.